Skip to main content

Table 1 Transitional Probabilities per Development Phase from 1993–2004

From: Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model

Therapeutic class Phase I-II (%) Phase II-III (%) Phase III- RR (%) RR-approval (%) Clinical approval success rate (%)
Anitneoplastic/immunologic 71.8 49.0 55.3 100 19.4
Cardiovascular 62.9 32.4 64.3 66.7 8.7
CNS 59.6 33.0 46.4 90.0 8.2
GI/metabolism 67.5 34.9 50.0 80.0 9.4
Musculoskeletal 72.4 35.2 80.0 100 20.4
Respiratory 72.5 20.0 85.7 80.0 9.9
Systemic anti-infective 58.2 52.2 78.6 100 23.9
Miscellaneous 62.8 48.7 69.8 91.3 19.5
  1. Notes: Through to June 2009.
  2. CNS, Central Nervous System; GI, gastrointestinal; RR, regulatory review.
  3. Source: [36] DiMasi, J.A., et al., Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs. Clin Pharmacol Ther, 2010. 87(3):272–277.